NCT05573282View on ClinicalTrials.gov

Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

October 16, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

January 1, 2026

Conditions
Hepatocellular Carcinoma
Interventions
OTHER

Regorafenib combine with ICIs

Regorafenib: 80mg/day, PO, QD, d1～d21, Q4W ICIs: 200mg/day, IV, d1,Q3W

Trial Locations (2)

500060

RECRUITING

Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center,, Guangzhou

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guanzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER